Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Post by PLITheOneon Jun 17, 2021 6:40am
141 Views
Post# 33400600

Expect

Expect

Expect another drop below $4 today, treading in the $3 territory by the end of this week into next. This declining trend will continue with no support or Thomvest manipulation. 

Did Liminal state that the plant was inspected and approved? If they were going to pay Kedrion to take this technology why would they have had the plant inspected? Is this a conditional FDA approval? They intend on closing Laval plant, probably because their scam is not welcome in Quebec anymore. Are they planning to build a new plant in Ontario or farm out Ryplasim production? Either way a lot more costs on the horizon.

The market doesn't like what it sees, the share price is bleeding not only because they will need funding, but because this is what Thomvest has always wanted.  

<< Previous
Bullboard Posts
Next >>